"Seeing is believing," the founder of lab company Truvian told me. So I tried its tabletop blood testing device—which promises results in 30 minutes—for myself.

In a report released today, Justin Smith from Bernstein maintained a Buy rating on Roche Holding AG (RHHVF – Research Report), with a price target of CHF345.00. The company’s shares closed ...

Roche (RHHBY) announced that the Food and Drug Administration has approved Susvimo 100 mg/mL for the treatment of diabetic macular edema, a leading cause of vision loss in adults with diabetes ...

Hoffmann-La Roche Limited (Roche Canada) announced that Health Canada has authorized Vabysmo (faricimab injection) for use in a 6.0 mg single-use pre-filled syringe (PFS) for use in the treatment of ...

La Roche-Posay is a trusted brand, offering an array of sunscreens, designed to cater to different skin requirements and types. When it comes to choosing the best La Roche-Posay sunscreen ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

1 Day RHHBY 2.56% DJIA 0.77% S&P 500 1.04% Health Care/Life Sciences 0.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit ...

Roche, Servicenow®, and Solventum. "The commitment of these industry leaders demonstrates the vital importance of collaboration in advancing healthcare technology," said Amanda Kavthekar ...

If anything, the gap understates the gulf between the soft-spoken, beetle-browed Hoffmann, who is the great-grandson of Fritz Hoffmann-La Roche, founder of pharmaceuticals group Roche, and the ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The overall dividend payment totals $9 million. “It was actually a great quarter for us,” CEO Pat Roche said in an interview, citing the strong sales and “impressive bookings that give us ...